Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine

Journal of Clinical Psychopharmacology

Volumn 20, Issue 3, 2000, Pages 311-316

  Chengappa, K N Roy ^a,b,c   Pollock, Bruce G ^a,c   Parepally, Haranath ^a,b   Levine, Joseph ^a,c   Kirshner, Margaret A ^a   Brar, Jaspreet S ^a   Zoretich, Rebecca A ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Spec Studs Ctr Mayview Stt Hosp   (United States)

^c Stanley Ctr Innov Treatm B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; SALIVATION DISORDER; SCHIZOIDISM; SCHIZOPHRENIA; SCORING SYSTEM; TACHYCARDIA; URINARY DYSFUNCTION;

ADULT; ANTIPSYCHOTIC AGENTS; ATROPINE; AUTONOMIC NERVOUS SYSTEM DISEASES; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; CLOZAPINE; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC;

EID: 0034030696     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200006000-00004     Document Type: Article

References (32)

1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radireceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14: 87-96.
2. Beasley CM Jr, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double bund olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
3. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective disorder and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
4. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
5. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57[Suppl 11]: 4-11.
6. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1996;58[Suppl 10]:55-62.
7. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means of assessing the risk of delirium. Am J Psychiatry 1992;149:1393-4.
8. Tune L, Coyle JT. Serum levels of anticholinergic drugs in the treatment of acute extrapyramidal side effects. Arch Gen Psychiatry 1980;37:293-7.
9. Pollock BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Mazumdar S, Reynolds CF III. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998;155:1110-2.
10. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76[Suppl 334]:11-100.
11. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
13. Woerner MC, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988;24:112-7.
14. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 1998;59:184-8.
15. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16[Suppl 2]:1S-9S.
16. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 1991;192:205-6.
17. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992;260:576-80.
18. Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic m4 receptor agonist. Eur J Pharmacol 1994; 69:R1-R2.
19. Olianas MC, Maullu C, Onali P. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 1997;122:401-8.
20. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
21. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
22. Eierman B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
23. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Swanson BJ, Hamman SP, Wrighton SA. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
24. Maenpaa J, Wrighton S, Bergstrom R, Cerimele B, Tatum D, Hatcher B, Callaghan JT. Pharmacokinetic (PK) and pharmacodynamic (PD). interactions between fluvoxamine and olanzapine [abstract]. Clin Pharmacol Ther 1997;61:225.
25. Haring C, Meise U, Humpel C, Sana A, Fleischhacker WW, Hinterhuber H. Dose-related plasma changes of clozapine: influence of smoking behavior, sex and age. Psychopharmacology (Berl) 1989;99[Suppl]:S38-S40.
26. Patel BR, Kurtz DL, Callaghan JT, Beasley CM Jr, Cerimele BJ, Bergstrom RF. Effects of smoking and gender on population pharmacokinetics of olanzapine (OL) in a phase III clinical trial [abstract], Pharm Res 1996;13[Suppl]:S408.
27. Patel BR, Nyhart EH Jr, Callaghan JT, Kassahun K, Hunt TL, Kurtz D, Bergstrom RF. Combined population pharmacokinetic analysis of olanzapine in healthy volunteers [abstract]. Pharm Res 1995;12[Suppl]:S360.
28. Tune L, Coyle JT. Acute extrapyramidal side-effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl) 1981;75:9-15.
29. Golinger RC, Peet T, Tune LE. Association of elevated plasma anticholinergic activity with delirium in surgical patients. Am J Psychiatry 1987;144:1218-20.
30. Tune L, Damlouji NF, Holland A, Gardener TJ, Folstein MF, Coyle JT. Association of post-operative delirium with raised serum levels of anticholinergic drugs. Lancet 1981;2:651-3.
31. Rovner B, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care capacity and anticholinergic drug levels in nursing home patients. Am J Psychiatry 1988;145:107-9.
32. Ganguli R, Brar JS, Vemulapally H, Jafar H, Ahuja R, Sharma S, Wirth, RJ. Mini-Mental State Examination (MMSE). performance of partially remitted community-dwelling patients with schizophrenia, Schizophr Res 1998;33:45-52.